KOD.US Kodiak Sciences Inc

Healthcare Biotechnology USA Stocks
111.19 USD
Close of Nov 15, 2026
18.15 112.79
Market cap
USD 7.27B
P/E
-
P/B
579.00x
ROE
-2,015.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is KOD.US undervalued?

Graham number

The Graham number of Kodiak Sciences Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kodiak Sciences Inc fundamental analysis

No fundamental analysis for Kodiak Sciences Inc yet.

Kodiak Sciences Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-relat…

Full company profile